Last checked at 3 Jan 2023 09:24
LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hikma Pharmaceuticals Share News (HIK)
HIK Share
Price
HIK Share
News
HIK Share
Chat
HIK Share
Trades1,249
HIK
Live RNS
HIK Share
Charts
HIK Level 2
Console
HIK Live
Share Price
HIK Broker
Ratings
HIK Directors
Deals
HIK Financial
Diary
HIK
Fundamentals
HIK Short
Positions
HIK
Media
Hikma Pharmaceuticals Information
Share Price Information for Hikma Pharmaceuticals (HIK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,913.00
Bid:
1,916.00
Ask:
1,918.00
Change:
59.00 (3.18%)
Spread:
2.00 (0.104%)
Open:
1,861.00
High:
1,920.00
Low:
1,861.00
Prev. Close:
1,854.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Hikma signs agreement with EffRx for licensing of osteoporosis treatment Binesto
Mon, 04th Feb 2013 10:37
FTSE 250-listed pharmaceuticals group Hikma Pharmaceuticals has signed an agreement with EffRx for the licensing and distribution of osteoporosis treatment Binosto.The treatment, which is to be distributed throughout the Middle East and North Africa (MENA), represents the only buffered solution for the treatment of osteoporosis, delivering fracture-risk reduction and offering the potential to improve adherence to therapy. Under the terms of the agreement, Hikma will have the exclusive rights to register, market and distribute Binosto in 19 countries across MENA. Mazen Darwazah, Vice Chairman and Chief Executive Officer of MENA for Hikma, said: "We are pleased to be licensing this excellent product from EffRx. The agreement supports our strategy to continue working with global partners to strengthen our product portfolio in growing therapeutic categories, including women's health. Hikma is committed to bringing a broad range of high quality, pharmaceutical products to patients in MENA." Christian Rosén, Chairman and Chief Executive Officer of EffRx Pharmaceuticals said: "We are thrilled to announce this partnership with Hikma, a company who we believe to be an ideal partner for EffRx in MENA. We believe Hikma's well-established sales force across the region can drive Binosto to a market leadership position and we are extremely proud to have Hikma as a partner."Hikma's share price was up 0.49% to 828p at 10:59.MF
More News
3 Jan 2023 09:03
LONDON MARKET OPEN: Stocks jump in first session of 2023
(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.
Read more3 Jan 2023 07:58
LONDON BRIEFING: Stocks called higher; China factory sector shrinks
(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.
Read more3 Jan 2023 07:46
Hikma launches generic narcolepsy solution in US
(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.
Read more8 Dec 2022 09:48
LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:
Read more6 Dec 2022 10:48
RBC Capital Markets starts Hikma at 'outperform'
(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.
Read more6 Dec 2022 10:26
LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read more15 Nov 2022 12:10
Credit Suisse initiates coverage of Hikma at 'outperform'
(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.
Read more15 Nov 2022 09:58
LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more14 Nov 2022 09:25
LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
Read more8 Nov 2022 09:39
LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more3 Nov 2022 11:17
Hikma Pharmaceuticals reiterates 2022 guidance as costs widen
(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.
Read more3 Nov 2022 11:08
3 Nov 2022 09:28
Banks, insurance dodge carnage as real estate stocks sink
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .
Read more3 Nov 2022 09:18
LONDON MARKET OPEN: BT results disappoint; pound falls on Fed outlook
(Alliance News) - Stock prices in London opened lower on Thursday, as the pound fell against a strengthening dollar, after the Federal Reserve indicated that US interest rates are likely to reach higher levels than previously thought.
Read more